Bio-Techne Corp. (TECH) PT Lowered to $61 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TECH Hot Sheet
Price: $72.73 +0.10%
Rating Summary:
6 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
6 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
RBC Capital analyst Conor McNamara lowered the price target on Bio-Techne Corp. (NASDAQ: TECH) to $61.00 (from $63.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Bio-Techne (TECH) Declares $0.08 Quarterly Dividend; 0.4% Yield
- Matador (MTDR) PT Raised to $66 at Truist Securities
- Pfizer (PFE) PT Raised to $40 at Argus
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
